Bimekizumab shows long-term efficacy in hidradenitis suppurativa

UCB’s BIMZELX reveals promising two-year data at EHSF 2025

UCB has announced impressive two-year data for BIMZELX (bimekizumab) at the 2025 EHSF.

The data from the BE HEARD trials highlight sustained disease control in moderate to severe hidradenitis suppurativa (HS).

After two years of treatment with bimekizumab, 53.1% of patients experienced mild disease compared to none at baseline. Moreover, 83.4% of patients remained flare-free and 86.9% of HiSCR75 responders at 48 weeks maintained their response. BIMZELX is the only approved medicine inhibiting both interleukin 17A (IL-17A) and interleukin 17F (IL-17F).

Professor Christos C. Zouboulis, President of the European Hidradenitis Suppurativa Foundation, emphasised the positive impact of these results.

He stated that the data show bimekizumab’s ability to provide sustained disease control, moving patients towards mild disease and offering hope for long-term management.

Among one-year responders to bimekizumab, over 85.0% maintained response across various endpoints. Improvements in disease severity were evident, with the majority shifting from severe to mild or moderate disease. The mean draining tunnel count also decreased over two years, with patients reporting improved health-related quality of life.

Fiona du Monceau, Executive Vice President and Head of Patient Evidence at UCB, expressed excitement about these findings.

She noted that sustained flare control and improvement in disease severity over two years demonstrate bimekizumab’s transformative potential for HS patients. UCB’s commitment to improving the lives of those with HS is reinforced by these positive results.

Abstracts of these findings will be presented at the 14th Conference of the European Hidradenitis Suppurativa Foundation in Vilnius.